Navigation Links
Aethlon Medical Announces Multi-Target Exosome Assay Validation
Date:4/12/2011

ancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
  • Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.  
  • Human Immunodeficiency Virus (HIV):  Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
  • Bioterror and Pandemic Threats:  Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

  • The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

    In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little
    '/>"/>

    SOURCE Aethlon Medical, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Aethlon Medical Releases Shareholder Letter
    2. Aethlon Medical Receives FDA Approval to Export its Hemopurifier® to India
    3. Aethlon Medical Releases Shareholder Letter
    4. Aethlon Medical to Host Investor Event on January 20, 2011
    5. Aethlon Medical Announces Presentation at U.S. Department of Health and Human Services BARDA Industry Day
    6. A Platform Technology to Address Bioterrorism Released by Aethlon Medical, Inc.
    7. Aethlon Medical to Present at the Singular Research Fifth Annual Best of the Uncovereds Conference
    8. Aethlon Medical Names Rod Kenley President
    9. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
    10. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
    11. Aethlon Medical Reestablishes Biodefense Programs
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 /PRNewswire/ ... they have entered into a license and collaboration ... target cancers. PhosImmune possesses technology for ... surfaces of tumor cells in association with HLA ... proteins that play a role in malignancy, are ...
    (Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 /PRNewswire/ ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting ... Under the terms of the collaboration, Foundation ... laboratory component of Foundation Medicine,s FoundationOne® assay at the ...
    (Date:10/20/2014)... 2014  ResMed (NYSE: RMD ) ... Exchange program, a comprehensive suite of software and ... other health care providers. ResMed ... patient information. It integrates valuable sleep and respiratory ... management platforms with customers, in-house or third-party electronic ...
    Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5ResMed Launches ResMed Data Exchange 2
    (Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
    (Date:10/22/2014)... Amy Norton HealthDay Reporter ... remain riveted on the three Ebola cases in Dallas. But, ... health threat to Americans. President Barack Obama on Friday ... the virus, which has infected two Dallas nurses who cared ... at Texas Health Presbyterian Hospital. But the U.S. cases ...
    (Date:10/22/2014)... 22, 2014 Hay House is pleased to ... and Upgrade Your Life (Paperback; $10.82) written by the highly ... Recovery. This book is meant to help readers of ... of recovery. , Recovery 2.0 is not the average ... 2.0 is a guide for what comes next. ...
    (Date:10/22/2014)... 2014 Healthcare professionals who are ... education at home or on-the-go via laptops, tablets ... brand new, premium Seminar-on-Demand CE courses. The new ... 2,000 hours of CE course offerings, ... experience. With such a diverse library, there’s something ...
    (Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
    Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
    ... , SCOTTSDALE, Ariz., Nov. 12 Healthcare Trust of ... investment trust, announced the execution of a Purchase and ... building located in Spartanburg, South Carolina for approximately $16,250,000. ... number of conditions. , The approximate 108,500 SF Mary ...
    ... MONTREAL, Nov. 12 The International Peak Performance Symposium ... - Via Scarlatti, 33 (close to Stazione Centrale), Milan ... , The conference will focus on the benefits that ... Peak Performance both in Sports and Business. Modern approaches ...
    ... found elevated amounts of protein involved in blood-brain barrier ... have a biological effect on the brain, but it,s ... risks, a Swedish medical researcher reports. , Fredrik Soderqvist, ... phone users and discovered they had elevated levels of ...
    ... that lead to myotonic dystrophy , THURSDAY, Nov. 12 (HealthDay ... pneumonia might serve as an effective treatment against a type ... mice and found that it appears to combat genetic defects ... types of muscular dystrophy. The muscle-wasting condition is also known ...
    ... Rats fed sugary chow suffered withdrawal when regular meals returned , ... of dieting? Join the club. But new research in rats hints ... as kicking drug addiction. , In the study, rats weaned off ... withdrawing from drugs and alcohol. , Rat brains aren,t the same ...
    ... ... facility in Lake Success, NY. The facility will house some of the practice’s ... M.D., Neuro-Ophthalmologist Scott Uretsky, M.D., Neuropsychologist Gad E. Klein, Ph.D. and Neurophysiologist Marat ... needs of pediatric patients. , ...
    Cached Medicine News:Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 108,500 SF Medical Office Building Located in Spartanburg, South Carolina 2Health News:Peak Performance, Neurofeedback and Biofeedback: New Frontiers of Empowerment From, and In, Sport 2Health News:Wireless Phones Alter Levels of Brain Chemical 2Health News:Study Links Yo-Yo Dieting to Addiction 2Health News:Study Links Yo-Yo Dieting to Addiction 3Health News:Neurological Surgery, P.C., of Long Island, NY, Adds New Specialists and Opens New Flagship Facility in Lake Success, NY 2Health News:Neurological Surgery, P.C., of Long Island, NY, Adds New Specialists and Opens New Flagship Facility in Lake Success, NY 3
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: